000 | 01951 a2200565 4500 | ||
---|---|---|---|
005 | 20250515202039.0 | ||
264 | 0 | _c20100625 | |
008 | 201006s 0 0 eng d | ||
022 | _a1527-9995 | ||
024 | 7 |
_a10.1016/j.urology.2009.04.101 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aGómez-Iturriaga Piña, Alfonso | |
245 | 0 | 0 |
_aMedian 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer. _h[electronic resource] |
260 |
_bUrology _cJun 2010 |
||
300 |
_a1412-6 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAge Factors |
650 | 0 | 4 | _aBiopsy, Needle |
650 | 0 | 4 |
_aBrachytherapy _xadverse effects |
650 | 0 | 4 | _aCohort Studies |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 |
_aErectile Dysfunction _xetiology |
650 | 0 | 4 | _aFollow-Up Studies |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImmunohistochemistry |
650 | 0 | 4 |
_aIodine Radioisotopes _xtherapeutic use |
650 | 0 | 4 | _aKaplan-Meier Estimate |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aNeoplasm Staging |
650 | 0 | 4 | _aProbability |
650 | 0 | 4 |
_aProstate-Specific Antigen _xblood |
650 | 0 | 4 |
_aProstatic Neoplasms _xmortality |
650 | 0 | 4 |
_aRadiation Injuries _xprevention & control |
650 | 0 | 4 | _aRadiotherapy Dosage |
650 | 0 | 4 |
_aRadiotherapy Planning, Computer-Assisted _xmethods |
650 | 0 | 4 | _aRelative Biological Effectiveness |
650 | 0 | 4 | _aRetrospective Studies |
650 | 0 | 4 | _aRisk Assessment |
650 | 0 | 4 | _aSurvival Rate |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aUrinary Incontinence _xetiology |
700 | 1 | _aCrook, Juanita | |
700 | 1 | _aBorg, Jette | |
700 | 1 | _aLockwood, Gina | |
700 | 1 | _aFleshner, Neil | |
773 | 0 |
_tUrology _gvol. 75 _gno. 6 _gp. 1412-6 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.urology.2009.04.101 _zAvailable from publisher's website |
999 |
_c19416052 _d19416052 |